341291

Kp7-6

≥98% (HPLC), lyophilized powder, Fas/FasL antagonist, Calbiochem^®

• Synonyme(s) : Fas/FasL Antagonist, Kp7-6, H-YC*DEHFC*Y-OH, Cyclic [Cys-Cys disulfide], Kp7-6
• Formule empirique (notation de Hill) : C₄₈H₅₆N₁₀O₁₅S₂
• Poids moléculaire : 1077.15
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: lyophilized powder
• Storage condition: OK to freeze, desiccated (hygroscopic), protect from light

Propriétés

• Nom du produit: Fas/FasL Antagonist, Kp7-6, The Fas/FasL Antagonist, Kp7-6 controls the biological activity of Fas/FasL. This small molecule/inhibitor is primarily used for Cancer applications.
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: lyophilized powder
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, desiccated (hygroscopic), protect from light
• color: white
• solubility: DMSO: 5 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C

Description

General description

An exocyclic cysteine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.

An exocyclic cystine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling pathways. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.

Biochem/physiol Actions

Cell permeable: no

Kd = 11.2 & 13.2 µM for FasL and Fas (CD95/APO-1), respectively

Primary Target
Fas/FasL-mediated cellular apoptotic signals

Product does not compete with ATP.

Reversible: no

Packaging

Packaged under inert gas

Physical form

Supplied as a trifluoroacetate salt.

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Carmona, E.M., et al. 2006. J. Immunol.177, 459.
Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA101, 6599.

H₂N-Tyr-Cys*-Asp-Glu-His-Phe-Cys*-Tyr-CO₂H, Cyclic [disulfide bond between Cys-Cys]

Legal Information

Sold under license of U.S. Patent 7,288,519.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Informations sur la sécurité

• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable